中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

4种评分系统对肝硬化合并感染患者预后的评估价值

姚运海 甘建和 赵卫峰

引用本文:
Citation:

4种评分系统对肝硬化合并感染患者预后的评估价值

DOI: 10.3969/j.issn.1001-5256.2019.01.016
基金项目: 

医学科学研究基金(YWJKJJHKYJJ-G17016); 

详细信息
  • 中图分类号: R575.2

Value of four scoring systems in evaluating the prognosis of cirrhotic patients with infection

Research funding: 

 

  • 摘要: 目的探讨Child-Turcotte-Pugh评分(CTP)、终末期肝病模型(MELD)评分、慢性肝衰竭-器官衰竭评分(CLIF-SOFA)以及亚太肝病学会慢加急性肝衰竭研究工作组评分(AARC)评价终末期肝病(ESLD)合并感染的预后价值。方法回顾性分析2014年1月-2017年12月苏州大学附属第一医院收治的肝硬化合并感染患者的临床资料,根据住院期间预后情况将患者分为内科综合治疗病情稳定者(A组)和住院期间治疗无效死亡、自动出院放弃治疗、内科治疗无效行肝移植者(B组)。比较2组患者一般资料,住院期间临床指标最差值,CTP评分、MELD评分、CLIF-SOFA评分、AARC评分、器官替代治疗(包括机械通气、人工肝支持系统、肾脏替代治疗等)。计量资料2组间比较采用t检验或Mann-Whitney U检验;计数资料2组间比较采用χ2检验。将单因素分析中差异有统计学意义的变量进行logistic回归分析;利用受试者工作特征曲线(ROC)分析4种评分系统预测患者预后效能。结果最终纳入522例肝硬化合并感染患者,存活381例,死亡141例,病死率为27. 01%。单因素分析显示PLT、TBil...

     

  • [1]BRUDEN DJT, McMAHON BJ, TOWNSHEND-BULSON L, et al.Risk of end-stage liver disease, hepatocellular carcinoma, and liver-related death by fibrosis stage in the hepatitis C Alaska Cohort[J].Hepatology, 2017, 66 (1) :37-45.
    [2]de MATTOSZ, de MATTOS AA.Model for end-stage liver disease-based allocation system:On the right path, but not there yet[J].Hepatology, 2016, 63 (1) :344.
    [3]Society of Infectious Diseases, Chinese Medical Association.Expert consensus on diagnosis and treatment of end-stage liver disease complicated infection[J].J Clin Hepatol, 2018, 34 (9) :1862-1872. (in Chinese) 中华医学会感染病学分会.终末期肝病合并感染诊治专家共识[J].临床肝胆病杂志, 2018, 34 (9) :1862-1872.
    [4]European Association for the Study of the Liver.EASL clinical practice guidelines for the management of patients with decompensated cirrhosis[J].J Hepatol, 2018, 69 (2) :406-460.
    [5]MARRERO JA, KULIK LM, SIRLIN CB, et al.Diagnosis, staging, and management of hepatocellular carcinoma:2018 practice guidance by the american association for the study of liver diseases[J].Hepatology, 2018, 68 (2) :723-750.
    [6]CAI J, ITO M, NAGATA H, et al.Treatment of liver failure in rats with end-stage cirrhosis by transplantation of immortalized hepatocytes[J].Hepatology, 2002, 36 (2) :386-394.
    [7]BERNARDI M, MOREAU R, ANGELI P, et al.Mechanisms of decompensation and organ failure in cirrhosis:From peripheral arterial vasodilation to systemic inflammation hypothesis[J].JHepatol, 2015, 63 (5) :1272-1284.
    [8]ACHARYA C, BAJAJ JS.The microbiome in cirrhosis and its complications[J].Clin Gastroenterol Hepatol, 2018.[Epub ahead of print]
    [9]SHIZUMA TS.Pontaneous bacterial and fungal peritonitis in patients with liver cirrhosis:A literature review[J].World JHepatol, 2018, 10 (2) :254-266.
    [10]Chinese Society of Hepatology, Chinese Medical Association.Guidelines on the management of ascites and complications in cirrhosis[J].J Clin Hepatol, 2017, 33 (10) :1847-1863. (in Chinese) 中华医学会肝病学分会.肝硬化腹水及相关并发症的诊疗指南[J].临床肝胆病杂志, 2017, 33 (10) :1847-1863.
    [11]LAN P, WANG SJ, SHI QC, et al.Comparison of the predictive value of scoring systems on the prognosis of cirrhotic patients with suspected infection[J].Medicine, 2018, 97 (28) :e11421.
    [12]KULKARNI S, SHARMA M, RAO PN, et al.Acute on chronic liver failure-in-hospital predictors of mortality in ICU[J].JClin Exp Hepatol, 2018, 8 (2) :144-155.
    [13]WU D, SUN Z, LIU X, et al.HINT:A novel prognostic model for patients with hepatitis B virus-related acute-on-chronic liver failure[J].Aliment Pharmacol Ther, 2018, 48 (7) :750-760.
    [14]LUO X, MASSIE AB, GENTRY SE, et al.MELD allocation system:There is always space to improve[J].Am J Transplant, 2018, 18 (11) :2834-2835.
    [15] SELVA RAJOO A, LIM SG, PHYO, et al.Acute-on-chronic liver failure in a multi-ethnic Asian city:A comparison of patients identified by Asia-Pacific Association for the Study of the Liver and European Association for the Study of the Liver definitions[J].World J Hepatol, 2017, 9 (28) :1133-1140.
    [16]BANSHO ETO, SILVA PES, COLOMBO BS, et al.Prognostic significance of the new criteria for acute kidney injury in cirrhosis[J].Ann Hepatol, 2018, 17 (3) :461-469.
    [17] ZHOU XD, CHEN QF, ZHANG MC, et al.Scoring model to predict outcome in critically ill cirrhotic patients with acute respiratory failure:Comparison with MELD scoring models and CLIF-SOFA score[J].Expert Rev Gastroenterol Hepatol, 2017, 11 (9) :857-864.
    [18]KANASHVILI B, SAGANELIDZE K, RATIANI L.The role of procalcitonin and blood lactic acid values in prognosis of sepsis and septic shock in polytrauma patients[J].Georgian Med News, 2018, N6 (279) :102-107.
    [19]CHOUDHURY A, JINDAL A, MAIWALL R, et al.Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF) :Comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models[J].Hepatol Int, 2017, 11 (5) :461-471.
    [20]ZHANG L, CHEN W, SHENG YJ, et al.Value of Model for EndStage Liver Disease score combined with neutrophil-lymphocyte ratio in predicting the short-term prognosis of patients with HBV-related acute-on-chronic liver failure[J].J Clin Hepatol, 2018, 34 (3) :553-557. (in Chinese) 张丽, 陈文, 盛云健, 等.MELD评分联合中性粒细胞/淋巴细胞比值对HBV相关慢加急性肝衰竭短期预后的预测价值[J].临床肝胆病杂志, 2018, 34 (3) :553-557.
    [21]SELVA-RAJOO A, LIM SG, PHYO WW, et al.Acute-onchronic liver failure in a multi-ethnic Asian city:A comparison of patients identified by Asia-Pacific Association for the Study of the Liver and European Association for the Study of the Liver definitions[J].World J Hepatol, 2017, 9 (28) :1133-1140.
    [22]ZHANG X, CHEN P, GAO H, et al.Bacterial infection and predictors of mortality in patients with autoimmune liver disease-associated acute-on-chronic liver failure[J].Can JGastroenterol Hepatol, 2018, 2018:5108781.
    [23]ZHOU XD, CHEN QF, ZHANG MC, et al.Scoring model to predict outcome in critically ill cirrhotic patients with acute respiratory failure:Comparison with MELD scoring models and CLIF-SOFA score[J].Expert Rev Gastroenterol Hepatol, 2017, 11 (9) :857-864.
    [24]BAO T, TAO B, GAO YF.Research Progress of antiviral efficacy in patients with chronic hepatitis B on predictors[J].JClin Hepatol, 2017, 33 (10) :1997-2000. (in Chinese) 鲍腾, 陶奔, 郜玉峰.慢性乙型肝炎患者抗病毒疗效预测指标的研究进展[J].临床肝胆病杂志, 2017, 33 (10) :1997-2000.
  • 加载中
计量
  • 文章访问数:  2004
  • HTML全文浏览量:  49
  • PDF下载量:  317
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-08-31
  • 出版日期:  2019-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回